Cypherpunk Technologies Inc. (FRA:5MC)

Germany flag Germany · Delayed Price · Currency is EUR
0.9100
0.00 (0.00%)
At close: Jan 9, 2026
-72.26%
Market Cap52.60M
Revenue (ttm)n/a
Net Income (ttm)-43.51M
Shares Outn/a
EPS (ttm)-1.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,300
Average Volume656
Open0.9600
Previous Close0.9100
Day's Range0.9100 - 0.9600
52-Week Range0.0280 - 3.2000
Betan/a
RSI45.70
Earnings DateMar 23, 2026

About Cypherpunk Technologies

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGe... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 52
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5MC
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.